CURR - CURE Pharmaceutical Holding Corp.

Other OTC - Other OTC Delayed Price. Currency in USD
4.8500
+0.5700 (+13.32%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close4.2800
Open4.3000
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range4.2600 - 4.8700
52 Week Range0.7200 - 4.9000
Volume137,943
Avg. Volume42,415
Market Cap209.254M
Beta (3Y Monthly)3.46
PE Ratio (TTM)N/A
EPS (TTM)-0.7080
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • GlobeNewswire6 days ago

    CURE Pharmaceutical and Canopy Growth to Produce CBD Oral Thin Films

    CURE Pharmaceutical (CURR), an innovative drug delivery and development company, today announced it is collaborating with Canopy Growth Corporation (WEED.TO) (CGC), (“Canopy”) to develop a new low-dose cannabidiol (CBD) oral thin film (OTF) using CURE’s patented CUREfilm™ technology for global distribution. “This collaboration builds on our licensing agreement with Canopy and accelerates product commercialization,” said Rob Davidson, CEO of CURE Pharmaceutical. CURE is registered with the U.S. Drug Enforcement Agency (DEA) to develop and manufacture cannabis-derived and synthetic cannabinoid-based products using its CUREfilm technology at its facility in Oxnard, Calif. With CUREfilm, the delivery of cannabinoids is easier and more effective as it offers increased bioavailability, ease and precision of dosing and greater palatability.

  • GlobeNewswire26 days ago

    CURE Pharmaceutical to Present at the 9th Annual LD Micro Invitational

    CURE Pharmaceutical (CURR), an innovative drug delivery and development company, today announced that it will be presenting at the 9th Annual LD Micro Invitational on Wednesday, June 5th at 11:40 a.m. PT at the Luxe Sunset Boulevard Hotel in Los Angeles. CEO Rob Davidson will be presenting and meeting with investors. “This is a period of fast-paced growth for our company with the addition of key hires to our leadership team and the acquisition of new patents and IP,” said Rob Davidson, CEO of CURE Pharmaceutical.

  • GlobeNewswirelast month

    CURE Pharmaceutical Secures Patent on Oral Thin Film Containing Bioactive Cannabinoid Molecules

    CURE Pharmaceutical (CURR), an innovative drug delivery and development company, today announced the issuance of U.S. Patent No. 10,307,397, which covers the high load of bioactive cannabinoid molecules integrated into oral thin film dosage forms. “Advances in drug delivery are critical to improving cannabis-based products,” said Rob Davidson, CEO of CURE Pharmaceutical. A higher load in oral thin film means 30 percent or more of the cannabinoid molecule is integrated.

  • GlobeNewswirelast month

    CURE Pharmaceutical Expands Leadership Team with Key New Hires

    CURE Pharmaceutical (CURR), an innovative drug delivery and development company, today announced the addition of four key hires to their growing leadership team. Michael Redard will serve as CURE’s Chief Financial Officer. Josh Held becomes an independent new board member, Bhaumik Patel is CURE’s director of new technologies and Teresa Virgallito will be a scientific advisor.

  • GlobeNewswirelast month

    CURE Pharmaceutical (OTCQB:CURR) Closes Acquisition Of Privately-Held Chemistry Holdings Inc.

    CURE Pharmaceutical (CURR) (“CURE”), an innovative drug delivery and development company, today announced that it has closed on the previously announced acquisition of Chemistry Holdings Inc. (“Chemistry Holdings”, “CH”), a formulation technology company that is developing innovative delivery systems for a variety of industries. The acquisition was an all-stock transaction using common stock. In connection with the signing and closing of this acquisition, CURE received a total of $10M in cash.

  • GlobeNewswire2 months ago

    Meroven LLC and CURE Pharmaceutical Enter Exclusive Marketing and Distribution Agreement for Spee-D for the USA

    Today, at the CPhI Conference, Meroven LLC announced a five-year agreement with CURE Pharmaceutical Corporation (CURR) to exclusively market and distribute Spee-D®, a weekly dose oral thin film Vitamin D3 in the USA. Under the terms of the agreement, Meroven LLC will be responsible for conducting all regulatory activities to obtain marketing authorizations for Spee-D as well as marketing and distribution. CURE will be responsible for the manufacture of Spee-D and its supply to Meroven at a predetermined transfer price.

  • GlobeNewswire2 months ago

    CURE Pharmaceutical Extends Closing Of Privately-Held Chemistry Holdings Inc. Acquisition to May 13

    CURE Pharmaceutical (CURR) (“CURE”), an innovative drug delivery and development company, today announced that it has extended the close of the previously announced acquisition of Chemistry Holdings Inc. (“Chemistry Holdings”, “CH”) to May 13, 2019. This merger transaction with Chemistry Holdings, a formulation technology company that is developing innovative delivery systems for a variety of industries was originally expected to be completed on April 30, 2019 and has been rescheduled to May 13, 2019. For more information about the innovative work from CURE Pharmaceutical, please visit its website at www.curepharma.com.

  • GlobeNewswire2 months ago

    Cure Pharmaceutical to Present at the “Planet MicroCap Showcase 2019”

    CURE CEO to discuss expanded product pipeline and company’s continued execution into cannabinoid market. LAS VEGAS, April 30, 2019 (GLOBE NEWSWIRE) -- CURE Pharmaceutical (CURR), an innovative drug delivery and development company, today announced that it will be presenting at the Planet MicroCap Showcase at 8:30 a.m. on Wednesday, May 1, 2019 and CEO Rob Davidson will conduct one-on-one meetings. “We are off to an exciting start in 2019 on many exciting fronts and building tremendous momentum as leaders in the burgeoning endocannabinoid market,” said Rob Davidson, CEO of CURE Pharmaceutical.

  • GlobeNewswire2 months ago

    CURE Pharmaceutical Named “Innovative Business of the Year” By Oxnard Chamber of Commerce 

    CURE Pharmaceutical (CURR) (“CURE”), an innovative drug delivery and development company, has been named 2019’s Innovative Business of the Year by Oxnard Chamber of Commerce in recognition to the company’s innovative thinking for various programs, employing pioneering technology and a dedication to improving the health of the community and world. The Oxnard Chamber of Commerce presented CURE Pharmaceutical with the “Innovative Business of the Year” award at its 69th Annual Community & Business Awards Dinner on Thursday, April 25 at 6:00 p.m. at Residence Inn by Marriott/River Ridge in Oxnard.

  • ACCESSWIRE2 months ago

    Uptick Newswire Hosts CURE Pharmaceutical on The Stock Day Podcast to Discuss Major Milestones and 2019 Goals

    PHOENIX, AZ / ACCESSWIRE / April 16, 2019 / Uptick Newswire Stock Day Podcast welcomed CURE Pharmaceutical (CURR) (''the Company''), a vertically integrated drug delivery and development company committed to improving drug efficacy, safety and the patient experience through its proprietary drug dosage forms and delivery systems. CEO Rob Davidson joined Stock Day host Everett Jolly.

  • GlobeNewswire3 months ago

    United Smart Cities and Cure Pharmaceutical Launch Global Healthcare Awareness Initiative

    CURE Pharmaceutical (CURR), an innovative drug delivery and development company, today announced a global healthcare awareness initiative with United Smart Cities for the purpose of educating, informing and providing the next generation healthcare solutions to the world’s 7.3 billion citizens. Recognizing escalating healthcare costs, CURE and United Smart Cities will seek to promote education and innovation in delivering cost-effective and sustainable treatments to the world’s population. “CURE was founded on the principles of affordability and global accessibility of medications,” said Rob Davidson, CEO of Cure Pharmaceutical.  “We are driven to finding healthcare solutions for people of all ages and demographics and we are honored to be in service to this cause with United Smart Cities.

  • GlobeNewswire3 months ago

    CURE Pharmaceutical to Acquire Privately-Held Chemistry Holdings Inc., Expanding Its Technology Platform in Oral Drug Delivery

    CURE Pharmaceutical (CURR) (“CURE”), an innovative drug delivery and development company, today announced that it has agreed to acquire Chemistry Holdings Inc. (“Chemistry Holdings”, “CH”), a formulation technology company that is developing innovative delivery systems for a variety of industries, in an all-stock transaction. “This transaction will create a pioneering drug delivery engine with the promise to transform patient experience and wellness,” said Rob Davidson, CEO of CURE Pharmaceutical.

  • GlobeNewswire3 months ago

    CURE Pharmaceutical Announces Completion of FDA Pre-IND Review and Clinical Trial Plans for CUREfilm Blue™ for Erectile Dysfunction

    CURE Pharmaceutical (CURR), an innovative drug delivery and development company, today announced it has successfully completed a pre-IND (Investigational New Drug) review with the U.S. Food and Drug Administration (FDA). The FDA provided feedback supportive of CURE’s clinical development plans for its CUREfilm Blue, a soluble thin film for oral administration of sildenafil citrate (Viagra™) to treat erectile dysfunction (ED).

  • Benzinga3 months ago

    CURE Pharmaceutical Expands DEA License To Manufacture Cannabinoid Molecules

    CURE Pharmaceutical Holding Corp (OTC: CURR ) said Tuesday it managed to broaden its license from the U.S. Drug Enforcement Administration. The expanded license as an authorized manufacturer of Schedule ...

  • GlobeNewswire3 months ago

    CURE Pharmaceutical Expands U.S. DEA Approval to Manufacture Pharmaceuticals Using Whole Cannabis Plant

    CURE Pharmaceutical (CURR), an innovative drug delivery and development company, today announced it has broadened its U.S. Drug Enforcement Administration (DEA) license as an authorized manufacturer of Schedule 1 substances to include both cannabis plant extracts and synthetic cannabidiol (CBD). This license allows CURE to take advantage of its latest U.S. Patent No. 10,238,705 issuing this month for the extraction and purification of cannabis plant material, as well as subsequent processing of cannabis extracts for drug formulation. CURE will develop and manufacture cannabis-derived and synthetic cannabidiol-based pharmaceutical products using its CUREfilm™ technology at its facility in Oxnard, Calif.  CUREfilm technology is ideal for the delivery of cannabinoids as it offers increased bioavailability, ease and precision of dosing and greater palatability.

  • GlobeNewswire5 months ago

    National Healthcare Economics and Policy Expert Ruben Jose King-Shaw Jr Joins CURE Pharmaceutical’s Board of Directors

    CURE Pharmaceutical (CURR), an innovative drug delivery and development company, today announced Ruben Jose King-Shaw Jr. has joined its Board of Directors. King-Shaw brings significant expertise in healthcare, government and finance. King-Shaw joins the recently named chairman William (Bill) Yuan and Dr. Gene Salkind, expanding the board to six.

  • GlobeNewswire5 months ago

    CURE Pharmaceutical Appoints Chairman, Adds Member to its Board of Directors

    CURE Pharmaceutical (CURR), an innovative drug delivery and development company, today announced it has appointed William (Bill) Yuan to Chairman of the Board and Dr. Gene Salkind to its Board of Directors.

  • GlobeNewswire5 months ago

    CURE Pharmaceutical To Present at Benzinga Cannabis Capital Conference

    CURE Pharmaceutical (CURR), an innovative drug delivery and development company, today announced that it will host an investor presentation at the Benzinga Cannabis Capital Conference at the Eden Roc Miami Beach Hotel in Miami on January 16, 2019 at 5pm. “This conference is the ideal kick-off to 2019, which is set to be a landmark year for the cannabis industry,” said Rob Davidson, CEO of CURE Pharmaceutical. If you would like to schedule a meeting with CURE Pharmaceutical, please contact Ashley Ray at aray@olmsteadwilliams.com.

  • GlobeNewswire7 months ago

    CURE Pharmaceutical Secures U.S. DEA Approval to Manufacture Cannabinoid-based Pharmaceuticals

    CURE Pharmaceutical (CURR), an innovative drug delivery and development company, today announced it has secured a new registration with the Drug Enforcement Administration (DEA) as a manufacturer authorized to handle Schedule 1 controlled substances. With this license, CURE will develop and manufacture cannabinoid-based pharmaceutical products using its CUREfilm™ technology at its facility in Oxnard, Calif. “This license enables CURE to translate the research findings from our collaboration with Technion – Israel Institute of Technology into potential treatments and expand our marketable product lines,” said Jessica Rousset, Chief Operating Officer of CURE Pharmaceutical.

  • GlobeNewswire7 months ago

    CURE Pharmaceutical Names Veteran Executive as Chief Financial Officer

    CURE Pharmaceutical (CURR), an innovative drug delivery and development company, today announced it has tapped Alex Katz to be the company’s Chief Financial Officer. Bringing his expertise in venture capital, Katz will oversee the company’s financial functions and investment relations. “Our company is approaching 2019 amidst exponential growth and a clear vision to be a leader in drug delivery innovation,” said Robert Davidson, CEO and Chairman of the Board of CURE Pharmaceutical.

  • GlobeNewswire8 months ago

    Prominent Biotech Investor Gene Salkind Adds Another $2M Investment in CURE Pharmaceutical

    CURE Pharmaceutical (CURR), an innovative drug delivery and development company, has announced that the company secured a $2 million investment at $2.5 per share from Gene Salkind, a company advisor and biotech investor, bringing his total investment in the company to $3 million. In February 2018, Dr. Salkind joined CURE’s advisory board to help advance CURE’s pipeline for the central nervous system and other therapeutic areas. “This second round of financing from Dr. Salkind is an example of the confidence our investors see in the company’s future,” said Robert Davidson, CEO and Chairman of the Board of CURE Pharmaceutical.